GENSCRIPT BIO (01548): Meng Jiangge appointed as a director of Legend Biotech
Kingstray Biotechnology (01548) announced that, starting from January 20, 2026, Legendary Biotechnology Limited ("Legendary"), a joint venture of the company and listed on the Nasdaq Global Select Market in the form of American Depositary Shares, has appointed Mr. Meng Jiange as a director, with an initial term until the annual shareholders' meeting of Legendary in 2026. Mr. Meng Jiange has been appointed to replace Dr. Zhu Li on the board of Legendary, who resigned from the position on the effective date.
GENSCRIPT BIO (01548) announces that Legend Biotech Corporation ("Legend"), a joint venture company of the company, whose shares are listed on the NASDAQ Global Select Market in the form of American depositary shares, has appointed Mr. Meng Jiange as a director of the board, with an initial term until the annual shareholder meeting of Legend in 2026. Mr. Meng Jiange has been appointed to replace Dr. Zhu Li on the board of Legend, effective from the date of appointment. Dr. Zhu Li has resigned from the position.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


